爱力根美学两项四期研究：GLP-1减重者面部医美治疗满意度显著提升，95.7%称仍像自己
加州Irvine—艾伯维（AbbVie，纽约证券交易所代码 ABBV）旗下爱力根美学（Allergan Aesthetics）11月8日公布两项四期临床研究的结果。两项研究均针对正在服用胰高血糖素样肽-1（GLP-1）药物的成年人，评估面部医美治疗的效果，数据在11月5日至8日于加州圣迭戈（San Diego）举行的2026年美国皮肤外科协会（ASDS）年会上发表。
服用 GLP-1 药物减重的人可能出现面部变化，包括面部容积流失与皮肤质量改变。名为 HARMONY IN DIVERSITY 的研究是首个在这一人群中评估神经毒素联合透明质酸（玻尿酸）填充剂治疗的研究。在其医学减重队列中，30名服用稳定剂量 GLP-1 药物的成年人接受了玻尿酸填充剂、onabotulinumtoxinA（肉毒毒素A型）注射及研究指定的护肤方案，治疗后30天的 FACE-Q 面部外观满意度平均分较治疗前提高42.4分，达到统计学显著，皮肤质量、心理功能与社会功能也显著改善。与治疗相关的不良事件多为轻微、非严重且无需干预即消退，未见毒素远端扩散的证据。
另一项名为 HALO 的四期研究评估全脸玻尿酸填充治疗。在25名参与者的中期分析中，FACE-Q 面部外观满意度平均分在第3个月时较治疗前提高39.6分；95.7%的参与者表示满意或非常满意于自己治疗后仍像自己，82.6%对自然外观表示满意或非常满意，88%对皮肤的自然观感表示满意。中期分析时报告的与治疗相关不良事件多为轻微、非严重。两项研究均为前瞻性、多中心、开放标签研究，满意度评分来自经验证的患者问卷（量表为0至100分，分值越高代表结果越好）。
研究者、皮肤科医生 Joely Kaufman-Janette 表示，服用 GLP-1 药物的人正在经历面部外观的真实变化，这些变化会影响自我形象与社交，有了针对这一人群的数据，医生能更清楚地设定预期、制定贴合其经历的治疗方案。艾伯维美学研发高级副总裁 Darin Messina 表示，随着时间推移，这类患者的医美需求可能变化、可能需要不止一种治疗方式，公司以组合方式研究旗下产品，为临床使用提供证据。
HARMONY IN DIVERSITY 研究共纳入美国10个中心的130名成年人，其中第一队列100名22至65岁的参与者接受了面部与颈部的多模式治疗，面部外观满意度平均提高42.0分。爱力根美学在本次年会上还发表了在研神经毒素 trenibotulinumtoxinE 的探索性数字图像分析、成纤维细胞来源外泌体精华的皮肤质量研究，以及冷冻溶脂联合电磁肌肉刺激的腹部塑形治疗顺序研究。
（来源：艾伯维）
Allergan Aesthetics: Two Phase 4 Studies Show Higher Facial Satisfaction in Adults on GLP-1 Medications, 95.7% Say They Still Look Like Themselves
Irvine, California — Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced results on November 8 from two Phase 4 studies of aesthetic treatment in adults on glucagon-like peptide-1 (GLP-1) medications. The data were presented at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting, held November 5-8 in San Diego, California.
People taking GLP-1 medications for weight loss may experience facial changes, including loss of facial volume and changes in skin quality. HARMONY IN DIVERSITY is the first study to evaluate a neurotoxin combined with hyaluronic acid (HA) injectables in this population. In its medical weight loss cohort, 30 adults on stable doses of GLP-1 medications received HA injectables, onabotulinumtoxinA and a study-specified skincare regimen; mean FACE-Q Satisfaction With Facial Appearance improved by a statistically significant 42.4 points from before treatment to 30 days after onabotulinumtoxinA treatment, with statistically significant improvements in skin quality, psychological function and social function. Most treatment-related treatment-emergent adverse events were mild, nonserious and resolved without intervention, and there was no evidence of distant spread of toxin.
In HALO, a second Phase 4 study of HA injectables across the face, an interim analysis of 25 adults on GLP-1 medications showed a 39.6-point mean improvement in FACE-Q Satisfaction With Facial Appearance at month 3. In addition, 95.7% of participants were satisfied or very satisfied that they still looked like themselves, 82.6% were satisfied or very satisfied with how natural they looked, and 88% were satisfied with how natural their skin looks. Most treatment-related adverse events reported at the time of the interim analysis were mild and nonserious. Both studies were prospective, multicenter and open-label, and used validated patient questionnaires scored from 0 to 100, with higher scores indicating better outcomes.
“Patients on GLP-1 medications are navigating real changes in how their face looks, and those changes can affect their self-image and how they engage with others,” said Joely Kaufman-Janette, M.D., a board-certified dermatologist and study investigator. “Having data specific to this population gives us a clearer starting point for setting expectations and building a treatment plan that reflects what they're experiencing.” Darin Messina, Ph.D., senior vice president and head of aesthetics research and development at AbbVie, said the company's research is designed around the patients it serves, including people taking GLP-1 medications for weight management, whose aesthetic concerns can change over time and may call for more than one treatment approach.
HARMONY IN DIVERSITY enrolled 130 adults across 10 U.S. sites; its first cohort of 100 participants ages 22-65 received multimodal treatment of the face and neck and recorded a 42.0-point mean improvement in facial appearance satisfaction. Allergan Aesthetics also presented an exploratory digital image analysis of the investigational neurotoxin trenibotulinumtoxinE (trenibotE), studies of a fibroblast-derived exosome serum for skin quality, and research on treatment sequencing for abdominal body contouring at the meeting.
(Source: AbbVie)
来源：艾伯维
发布：GSM·美国（发布链接）
图片来源：图：爱力根（Allergan）位于加州 Irvine 的总部大楼（资料图）。Coolcaesar 摄，CC BY-SA 3.0，经 Wikimedia Commons。 / Photo: Allergan headquarters in Irvine, California (file photo). Photo by Coolcaesar, CC BY-SA 3.0, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
